STOCK TITAN

Daxor Corporation - DXR STOCK NEWS

Welcome to our dedicated page for Daxor Corporation news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor Corporation stock.

Daxor Corporation Common Stock (DXR) represents a pioneering medical instrumentation and biotechnology company focused on the accurate measurement of blood volume. Daxor develops and markets the BVA-100 (Blood Volume Analyzer), which stands as the first FDA-cleared diagnostic tool capable of providing precise, objective quantification of blood volume status and composition compared to patient-specific norms. This technology is pivotal across a wide range of medical conditions.

The BVA-100 has revolutionized blood volume measurement, a practice that has historically been prone to lengthy and inaccurate testing processes. Traditional methods often took 4 to 8 hours and yielded inconsistent results. In contrast, the BVA-100 can deliver accurate and reliable measurements quickly, enhancing the capabilities of physicians who previously had to rely on less precise tests that measured blood thickness, often leading to misleading outcomes in critical medical situations.

Daxor Corporation, headquartered in New York, is at the forefront of medical technology and innovation. The company's recent achievements include the development of the next generation of Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes. These advancements are not only enhancing the quality of patient care but also strengthening the company's market position.

Financially, Daxor has shown robust growth, with unaudited revenue climbing 229.1% in the first two months of 2024 year-on-year. The company's strong start to 2024 is indicative of its commitment to innovation and excellence. Daxor is also actively engaged in strategic partnerships and investor relations, with Bret Shapiro serving as the Senior Managing Partner at CORE IR, ensuring transparent and effective communication with investors and stakeholders.

In addition to its technological developments, Daxor is also a notable presence in the medical community, participating in significant events such as the Premier Event for Cardiovascular Industry Leaders and Clinicians. The company's research and publications, such as those presented at the American College of Cardiology Scientific Sessions and in the American Heart Journal, underscore its dedication to advancing medical knowledge and practice.

Rhea-AI Summary
Daxor (DXR) acquires exclusive rights and intellectual property for Volumex, Megatope, and Glofil from Iso-Tex Diagnostics, Inc. The acquisitions are expected to boost margins, increase revenue streams, and be cash flow positive immediately upon transfer of manufacturing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.74%
Tags
-
Rhea-AI Summary
Daxor (Nasdaq: DXR) to host an investor call on March 25, 2024, to review financial results and corporate developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.59%
Tags
-
Rhea-AI Summary
Daxor (DXR) provided a corporate update highlighting significant progress in revenue growth, new customer acquisitions, and advancements in blood volume measurement technology. The company reported an increase in net asset value, successful clinical studies, new patents, and upcoming product launches. Daxor's focus on accurate blood volume measurement aims to improve patient outcomes and reduce healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
Rhea-AI Summary
Daxor (DXR) reports a strong start to 2024 with unaudited revenue climbing 229.1% in the first two months of 2024 compared to the same period in 2023. The company's revenue increased by 31.8% in 2023 compared to 2022. The number of kits sold for their Diagnostic System rose by 36.2% in 2023. Daxor also launched 12 new accounts in 2023 and 6 new accounts in the first two months of 2024. The company anticipates breaking even within 12 months if FDA clearance for new units is obtained.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) expands blood volume analysis (BVA) in three new hospitals through new analyzer purchases and ezBVA Lab service utilization. The new acquisitions drive BVA sales growth and highlight its clinical importance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.43%
Tags
none
-
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) announces new data from Duke University Medical Center validating the benefits of blood volume analysis (BVA) in heart failure patients with impaired renal function. The study showed the limitations of surrogate markers compared to Daxor's 98% accurate BVA system, emphasizing the importance of accurate blood volume measurement in optimizing therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
Rhea-AI Summary
Daxor Corporation (NASDAQ: DXR) will be showcasing its innovative blood volume analysis (BVA) diagnostic at the Technology and Heart Failure Therapeutics Conference. BVA guided treatment in heart failure has demonstrated significant reductions in readmissions, mortality, and length of stay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
none
-
Rhea-AI Summary
Daxor Corporation (DXR) announces two significant customer transactions in January 2024, showcasing a strong start to the year. The new wins include a four-year lease agreement for the BVA analyzer at a network of 24 hospitals and a purchase at a 200-bed independent hospital. Dr. Aaron Earles praises the BVA technology for its impact on patient care. CEO Michael Feldschuh highlights the company's focus on commercialization and expanding market reach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) announces the expansion of blood volume analysis (BVA) through new analyzer purchases and the utilization of Daxor’s ezBVA Lab service. Q4-2023 sales wins include BVA analyzer purchases and rentals at various healthcare organizations, leading to a strong position for growth in 2024. CEO Michael Feldschuh emphasizes the focus on broadening commercial reach, integrating with new hospital systems, and strengthening clinical and health economic evidence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) will be exhibiting at the SNMMI Mid-Winter and ACNM Annual Meeting to raise awareness and educate members about their blood volume measurement technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
none

FAQ

What is the current stock price of Daxor Corporation (DXR)?

The current stock price of Daxor Corporation (DXR) is $8.2999 as of December 23, 2024.

What is the market cap of Daxor Corporation (DXR)?

The market cap of Daxor Corporation (DXR) is approximately 40.8M.

What does Daxor Corporation specialize in?

Daxor Corporation specializes in medical instrumentation and biotechnology, with a focus on precise blood volume measurement using their BVA-100 system.

What is the BVA-100?

The BVA-100 is a Blood Volume Analyzer, the first FDA-cleared diagnostic tool that provides accurate quantification of blood volume and composition.

How has the BVA-100 improved blood volume measurement?

The BVA-100 provides quick, accurate, and reliable blood volume measurements, overcoming the lengthy and inaccurate traditional methods.

What are some recent achievements of Daxor Corporation?

Recent achievements include the development of the next generation Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes.

How has Daxor performed financially in early 2024?

Daxor reported a strong start to 2024 with unaudited revenue climbing 229.1% in the first two months year-on-year.

Who is the Investor Relations Contact at Daxor Corporation?

Bret Shapiro, the Senior Managing Partner at CORE IR, is the Investor Relations Contact for Daxor Corporation.

What kind of medical events does Daxor participate in?

Daxor participates in significant medical events like the Premier Event for Cardiovascular Industry Leaders and Clinicians.

Where has Daxor Corporation published its research findings?

Daxor has presented data at the American College of Cardiology Scientific Sessions and published research in the American Heart Journal.

What is the significance of the BVA-100 in medical practice?

The BVA-100 provides physicians with accurate blood volume data, improving diagnosis and treatment in various medical and surgical situations.

Where is Daxor Corporation headquartered?

Daxor Corporation is headquartered in New York.

Daxor Corporation

Nasdaq:DXR

DXR Rankings

DXR Stock Data

40.78M
2.03M
56.52%
1.94%
0.13%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK